Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.40 |
| ▸ | GPR3 | P46089 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
| ▸ | SELE | P16581 | 1/20 | 0.37 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | ADK | P55263 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL924654 | 0.79 | LIMK1 (0.56) | LIMK1CDK5CDK5R1GPR3MAPT | |
| SCHEMBL17109971 | 0.79 | LIMK1 (0.40) | LIMK1CDK5CDK5R1GPR3MAPT | |
| SCHEMBL12903904 | 0.79 | LIMK1 (0.40) | LIMK1CDK5CDK5R1GPR3SMN1; SMN2 | |
| SCHEMBL2313439 | 0.77 | SMN1; SMN2 (0.46) | ADORA3ADORA2ASMN1; SMN2MAPTHTT | |
| SCHEMBL18370866 | 0.76 | ADORA2A (0.47) | LIMK1CDK5CDK5R1GPR3ADORA2A | |
| SCHEMBL24057409 | 0.75 | AURKA (0.41) | LIMK1CDK5CDK5R1GPR3SMN1; SMN2 | |
| SCHEMBL17287232 | 0.75 | ELANE (0.41) | GPR3SMN1; SMN2MAPTKMT2ALOXL2 | |
| SCHEMBL21164751 | 0.75 | MRGPRX1 (0.37) | LIMK1CDK5CDK5R1GPR3MAPT | |
| SCHEMBL19118255 | 0.74 | ELANE (0.43) | GPR3SMN1; SMN2MAPTLOXL2LMNA | |
| SCHEMBL16693475 | 0.74 | LOXL2 (0.43) | GPR3SMN1; SMN2MAPTHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230172057-A1 | HETEROCYCLIC COMPOUND CONTAINING HETEROATOM SUBSTITUTED FLUORENE AND OPTOELECTRONIC DEVICE | WUHAN TIANMA MICRO-ELECTRONICS CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230172057-A1 | HETEROCYCLIC COMPOUND CONTAINING HETEROATOM SUBSTITUTED FLUORENE AND OPTOELECTRONIC DEVICE | WUHAN TIANMA MICRO-ELECTRONICS CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-9790234-B2 | IRAK inhibitors and uses thereof | NIMBUS IRIS, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9790234-B2 | IRAK inhibitors and uses thereof | NIMBUS IRIS, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9790234-B2 | IRAK inhibitors and uses thereof | NIMBUS IRIS, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170081340-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS INC (US) | 2017-03-23 | — | — | US | disclosed |
| US-20170081340-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS INC (US) | 2017-03-23 | — | — | US | disclosed |
| US-20170081340-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS INC (US) | 2017-03-23 | — | — | US | disclosed |
| US-9481687-B2 | IRAK inhibitors and uses thereof | NIMBUS IRIS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-9481687-B2 | IRAK inhibitors and uses thereof | NIMBUS IRIS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| EP-2872144-A1 | IRAK INHIBITORS AND USES THEREOF | Nimbus Iris, Inc. (US) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014194242-A2 | FLT3 INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2014-12-04 | — | — | WO | disclosed |
| WO-2014011902-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2014-01-16 | — | — | WO | disclosed |
| WO-2014011902-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2014-01-16 | — | — | WO | disclosed |
| US-20140018343-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. | 2014-01-16 | — | — | US | disclosed |
| US-20140018343-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. | 2014-01-16 | — | — | US | disclosed |
| US-20140018343-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. | 2014-01-16 | — | — | US | disclosed |
| US-6596726-B1 | Method of inhibiting epidermal growth factor by treating, with an effective inhibiting amount, a mammal, in need thereof inhibit the epidermal growth factor receptor and related receptors and, in particular, their tyrosine kinase enzyme | WARNER LAMBERT COMPANY | 2003-07-22 | — | — | US | disclosed |
| EP-0741711-A1 | TRICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1996-11-13 | — | — | EP | disclosed |
| WO-1995019970-A1 | TRICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1995-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230172057-A1 | HETEROCYCLIC COMPOUND CONTAINING HETEROATOM SUBSTITUTED FLUORENE AND OPTOELECTRONIC DEVICE | CHRM1, CHRM2, CHRM4 | PDE4A 4447/4885PDE4B 4316/4885PDE4C 4322/4885 |
| US-20170081340-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK4, IRAK2, IRAK1 | PDE4A 1146/4885PDE4B 1162/4885PDE4C 1351/4885 |
| US-20140018343-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK4, IRAK2, IRAK1 | PDE4A 1146/4885PDE4B 1162/4885PDE4C 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.